Breast Cancer Screening Strategies and Their Effectiveness

Breast cancer screening encompasses a range of approaches designed to detect disease at earlier, more treatable stages, thereby reducing mortality. Mammography remains the cornerstone of screening in high-resource settings, with biennial or annual programmes tailored by age and risk. Advances such as digital breast tomosynthesis, adjunct ultrasonography and magnetic resonance imaging have enhanced detection, particularly in women with dense breast tissue, though they carry higher costs and variable false-positive rates. Clinical breast examination has demonstrated value in low-resource settings, providing a downstaging effect where imaging infrastructure is limited. Risk-stratified strategies, incorporating family history, breast density and polygenic profiles, have the potential to optimise benefit-to-harm ratios by concentrating resources on those at greatest risk and reducing overdiagnosis in lower-risk groups. Emerging tools, including artificial intelligence models for image interpretation, promise further refinement but must be carefully calibrated to representative populations to avoid skewed detection rates. Across all strategies, balancing earlier detection against harms such as overdiagnosis, false positives and anxiety remains central to effective programme design. Economic evaluations and modelling studies guide policy by weighing lives saved and quality-adjusted life-years gained against resource demands and unintended consequences, informing guidelines that adapt to diverse healthcare contexts worldwide.

Research from Nature Portfolio

A major consensus statement has outlined priorities for personalised early detection and prevention, advocating development of subtype-specific risk assessment tools applicable across ancestries, identification of intermediate surrogate markers for preventive interventions and evaluation of hybrid effectiveness–implementation models. It emphasises the need for novel non-surgical preventive measures, dynamic risk-based screening policies that evolve as new evidence emerges, and stakeholder engagement to ensure programmes align with societal values and legal frameworks. Modelling studies linked to this effort project long-term population outcomes of risk-based approaches, highlighting the potential to reduce harms while maintaining or improving cancer-specific survival.

Breast Cancer Screening Strategies and Their Effectiveness publication trend

The graph below shows the total number of articles in breast cancer screening strategies and their effectiveness across all publications each year (not limited to Nature Index journals).

Technical terms

Mammography: Radiographic imaging technique used to visualise internal breast structure for early cancer detection.

Overdiagnosis: Detection of cancers that would not have become clinically significant in a patient’s lifetime.

False positive: A test result indicating presence of disease when none exists, often leading to additional investigations.

Risk stratification: Classification of individuals into groups based on predicted disease risk to tailor screening intensity.

Quality-adjusted life-year (QALY): A metric combining quantity and quality of life to assess health interventions’ value.

References

1. Simulating mismatch between calibration and target population in AI for mammography the retrospective VAIB study. npj Digital Medicine (2025).
2. Breast Cancer Incidence After a False-Positive Mammography Result. JAMA Oncology (2024).
3. Cost-effectiveness and Benefit-to-Harm Ratio of Risk-Stratified Screening for Breast Cancer: A Life-Table Model. JAMA Oncology (2018).
4. Personalized early detection and prevention of breast cancer: ENVISION consensus statement. Nature Reviews Clinical Oncology (2020).
5. Effect of screening by clinical breast examination on breast cancer incidence and mortality after 20 years: prospective, cluster randomised controlled trial in Mumbai. The BMJ (2021).